DEA’s proposed rule to schedule tianeptine as a controlled substance rests on exposure data, poison-center calls climbing roughly 1,400 percent between 2015 and 2023, forensic encounters, and documented fatalities, evidence about consequences, not mechanism. A new study in Neuropharmacology supplies the mechanism directly. Tianeptine, given to rats, produces a specific pattern of hippocampal brain activity that an established opioid drug also produces, and that naloxone, the standard opioid antagonist, blocks entirely. Ketamine, tested in the identical paradigm, does neither.
How the study was designed
A University of Dundee team, first author Scott Burt with senior author Stephen Martin, recorded electrical activity directly from the hippocampus of anesthetized rats after injecting tianeptine at two doses, then compared the resulting pattern against buprenorphine, an established opioid, and separately against ketamine, another atypical antidepressant that shares tianeptine’s rapid, non-traditional mechanism reputation. Tianeptine produced a dose-dependent increase in beta-frequency brain activity, a specific electrical signature, and this effect was blocked completely by naloxone. Buprenorphine, the opioid used for comparison, produced a closely similar pattern. Ketamine did not: it generated a distinct, naloxone-insensitive change in a different frequency band entirely, evidence that whatever ketamine is doing to this same circuit runs through a different pathway altogether. The beta oscillation is the clean result here, present, dose-dependent, and opioid-blocked, in a way the study’s other physiological measure was not.
That other measure, a modest strengthening of synaptic transmission in the same hippocampal circuit, complicates rather than reinforces the picture. The paper reports that this fEPSP change tracked with the roughly 0.6 degree Celsius rise in brain temperature the higher tianeptine dose produced, alongside buprenorphine, while the beta oscillation itself was not predicted by that same temperature change. In other words, the synaptic finding may be at least partly a downstream consequence of hyperthermia rather than an independent, opioid-specific circuit effect the way the beta oscillation appears to be. Hyperthermia is itself a recognized risk factor in opioid toxicity generally, so this does not undercut the opioid-mechanism argument the study supports, but it means the two physiological findings should be read as separate threads, one a clean, naloxone-blocked signature, the other a temperature-linked effect worth its own follow-up, rather than a single unified result.
Why the comparison matters more than either result alone
Tianeptine’s manufacturer and defenders have long described it as an atypical antidepressant, a category that includes ketamine and shares little regulatory stigma with opioids specifically. This study does not simply show tianeptine has some opioid-related activity, prior work already established that its antidepressant-like effects in animals depend partly on opioid receptor activation. What this specific experiment adds is a direct, side-by-side comparison, in the same brain circuit, using the same measurement, showing tianeptine’s electrical signature groups with an opioid and separates cleanly from another atypical antidepressant it is otherwise often mentioned alongside. That is a more specific and more useful piece of evidence for classification purposes than either fact alone would be.
The caveats
This is anesthetized rat data measuring a specific electrophysiological signature, not a clinical study, and it does not by itself establish that tianeptine produces opioid-like abuse liability or withdrawal in humans at the doses being reported in DEA’s exposure data. The study was not designed to test abuse potential directly, and translating a hippocampal oscillation finding into a regulatory abuse-liability argument requires additional evidence this paper does not supply. It is mechanistic support for a classification argument already being made on other grounds, not a standalone case for scheduling.
The frame
DEA’s proposed rule was always going to be decided on exposure and harm data, not basic neuroscience, and nothing here changes that regulatory calculus directly. What this study does is give the field, and eventually DEA’s own rulemaking record, a piece of mechanistic evidence that was previously missing: a specific, comparative demonstration that tianeptine’s brain effects pattern with an opioid rather than with the atypical antidepressant it is most often grouped alongside. The public comment period on DEA’s proposed rule closed August 7. For a compound whose regulatory fate depends partly on whether it gets read as an opioid-adjacent risk or a conventional antidepressant with an unusual side effect profile, that comparison is exactly the kind of evidence worth having on the rulemaking record as DEA now weighs a final rule.